Skip to main content

Table 1 Demographic and clinical parameters of 50 patients with mRCC treated with sunitinib

From: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

Variables All cases (n = 50) CR/PR (n = 12) SD (n = 22) PD (n = 6) NE (n = 10) P value
Age [median (IQR)] 64 (58–71) 63 (56–77) 63 (57–67) 61 (56–66) 70 (64–76) 0.16
Follow-up months [median (IQR)] 20 (10–25) 21 (15–25) 22 (13–30) 12 (6–23) 18 (7–25) 0.38
Gender       0.51
 Male 40 (80 %) 10 (83 %) 17 (77 %) 6 (100 %) 7 (70 %)  
 Female 10 (20 %) 2 (17 %) 5 (23 %) 0 (0 %) 3 (30 %)  
Prior nephrectomy       0.95
 Yes 44 (88 %) 11 (92 %) 19 (86 %) 5 (83 %) 9 (90 %)  
 No 6 (12 %) 1 (8 %) 3 (14 %) 1 (17 %) 1 (10 %)  
Tumor histology       0.41
 Clear cell 40 (80 %) 11 (92 %) 15 (68 %) 5 (83 %) 9 (90 %)  
 Non-clear cell 4 (8 %) 0 (0 %) 4 (18 %) 0 (0 %) 0 (0 %)  
 Unknown 6 (12 %) 2 (17 %) 3 (14 %) 1 (17 %) 1 (10 %)  
 Concomitant sarcomatoid variant 2 (4 %) 0 (0 %) 0 (0 %) 1 (17 %) 1 (10 %)  
ECOG-PS       0.06
 0/1 41 (82 %) 11 (92 %) 19 (86 %) 5 (83 %) 5 (50 %)  
 2/3 9 (18 %) 1 (8 %) 3 (14 %) 1 (17 %) 5 (50 %)  
Metastatic sites       0.24
 Lung 28 (56 %) 7 (58 %) 12 (55 %) 5 (83 %) 4 (40 %)  
 Lymph nodes 12 (24 %) 3 (25 %) 8 (36 %) 2 (33 %) 1 (10 %)  
 Bone 19 (38 %) 2 (17 %) 10 (45 %) 0 (0 %) 5 (50 %)  
 Liver 4 (8 %) 1 (8 %) 1 (5 %) 1 (17 %) 1 (10 %)  
 Pancreas 2 (4 %) 2 (17 %) 0 (0 %) 0 (0 %) 0 (0 %)  
Heng risk group       0.016
 Favorable 10 (20 %) 3 (25 %) 5 (23 %) 1 (17 %) 1 (10 %)  
 Intermediate 29 (58 %) 8 (67 %) 14 (63 %) 3 (50 %) 4 (40 %)  
 Poor 11 (22 %) 1 (8 %) 3 (14 %) 2 (33 %) 5 (50 %)  
Serum CRP (mg/dL) (mean ± SEM) 2.70 ± 0.61 1.35 ± 0.78 2.79 ± 0.90 2.62 ± 1.43 4.18 ± 1.98 0.41
Serum sodium (mmol/L) (mean ± SEM) 139.4 ± 0.38 139.8 ± 0.59 140.3 ± 0.43 138.7 ± 1.26 137.4 ± 1.08 0.09
  1. IQR interquartile range; ECOG-PS Eastern Cooperative Oncology Group-perfomance status; CRP C-reactive protein; CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluated; SEM standard error of mean
  2. Kruskal–Wallis test;  Chi square test or Fisher’s exact test